文献速递慢阻肺

三种单吸入器双支气管扩张剂治疗慢阻肺的真实世界比较有效性

Real-world comparative effectiveness of three single-inhaler dual bronchodilators for the treatment of COPD.
PubMed 文献 · Eur Respir J · 2023-08-03

基于英国CPRD真实世界数据,纳入2017-2020年≥40岁、未用吸入激素的慢阻肺患者,倾向评分加权后比较三种双支气管扩张剂。VIL-UME相比OLO-TIO可降低中重度急性加重风险(HR 0.91, 95%CI 0.85-0.97),但与IND-GLY无差异;三者重度急性加重风险相似。VIL-UME全因死亡风险低于IND-GLY。

要点

  • VIL-UME较OLO-TIO降低中重度急性加重风险(HR 0.91, 95%CI 0.85-0.97)。
  • 三种双支气管扩张剂的重度急性加重风险无显著差异。
  • VIL-UME全因死亡风险低于IND-GLY(HR 0.82, 95%CI 0.68-0.98)。

核心结论

  • 三种双支气管扩张剂在真实世界中对重度急性加重风险的效果相似。
  • VIL-UME和IND-GLY在降低中重度急性加重风险方面可能略优于OLO-TIO。
  • VIL-UME可能降低全因死亡风险,值得进一步研究。

研究设计与样本

  • 基于英国临床实践研究数据链(CPRD)的真实世界队列研究。
  • 纳入2017-2020年≥40岁、未使用吸入激素的慢阻肺患者。
  • 采用倾向评分加权调整混杂因素。

主要发现

  • VIL-UME相比OLO-TIO的中重度急性加重HR为0.91(95%CI 0.85-0.97)。
  • VIL-UME相比IND-GLY的中重度急性加重HR为0.96(95%CI 0.89-1.03)。
  • VIL-UME相比OLO-TIO的重度急性加重HR为1.04(95%CI 0.86-1.26)。
  • VIL-UME相比IND-GLY的重度急性加重HR为1.05(95%CI 0.86-1.28)。
  • VIL-UME相比IND-GLY的全因死亡HR为0.82(95%CI 0.68-0.98),相比OLO-TIO的HR为0.87(95%CI 0.72-1.04)。

临床怎么用

  • 对于慢阻肺起始双支气管扩张剂治疗,三种组合对重度急性加重预防效果相当。
  • 若关注中重度急性加重风险,VIL-UME或IND-GLY可能略优于OLO-TIO。
  • VIL-UME与IND-GLY相比可能降低全因死亡风险,但需进一步验证。

局限性

  • 观察性研究设计可能残留混杂。
  • 仅纳入未使用吸入激素的患者,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Single-inhaler dual bronchodilators are now recommended as initial treatment of COPD for patients with multiple exacerbations or with moderate or severe dyspnoea. It is unclear whether there are differences in effectiveness among commonly used dual bronchodilators. METHODS: We identified a cohort of COPD patients, aged ≥40 years, treated during 2017-2020, from the UK Clinical Practice Research Datalink, a real-world practice setting. Inhaled corticosteroid-naïve patients initiating vilanterol-umeclidinium (VIL-UME) were compared with those initiating olodaterol-tiotropium (OLO-TIO) or indacaterol-glycopyrronium (IND-GLY) dual bronchodilators primarily on the incidence of moderate and severe COPD exacerbation over 1 year, and corresponding hazard ratios (HRs), after adjustment by propensity score weighting. RESULTS: The cohort included 15 224 initiators of VIL-UME, 5536 initiators of OLO-TIO and 5059 initiators of IND-GLY. The HR of a moderate or severe exacerbation with VIL-UME was 0.91 (95% CI 0.85-0.97) compared with OLO-TIO and 0.96 (95% CI 0.89-1.03) compared with IND-GLY. The risk of severe exacerbation was not different for VIL-UME when compared with OLO-TIO (HR 1.04, 95% CI 0.86-1.26) and IND-GLY (HR 1.05, 95% CI 0.86-1.28). All-cause mortality was lower with VIL-UME compared with IND-GLY (HR 0.82, 95% CI 0.68-0.98), but not compared with OLO-TIO (HR 0.87, 95% CI 0.72-1.04). CONCLUSION: In a real-world setting of COPD treatment, the three dual bronchodilator combinations were similarly effective on the risk of a severe exacerbation of COPD. However, the VIL-UME and IND-GLY combinations may confer slightly superior effectiveness than OLO-TIO on the risk of moderate or severe exacerbation. The potential lower mortality with VIL-UME warrants further investigation.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Li, Dell'Aniello, Ernst, et al. Real-world comparative effectiveness of three single-inhaler dual bronchodilators for the treatment of COPD. Eur Respir J. 2023. PMID: 37343975. doi:10.1183/13993003.00538-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。